Conference Call Participants
Alexandria Hammond – Wolfe Research, LLC
Terence Flynn – Morgan Stanley, Research Division
David Risinger – Leerink Partners LLC, Research Division
Evan Seigerman – BMO Capital Markets Equity Research
Louise Chen – Scotiabank Global Banking and Markets, Research Division
Geoffrey Meacham – Citigroup Inc., Research Division
Jason Gerberry – BofA Securities, Research Division
Mohit Bansal – Wells Fargo Securities, LLC, Research Division
Christopher Schott – JPMorgan Chase & Co, Research Division
Courtney Breen – Sanford C. Bernstein & Co., LLC., Research Division
Carter Gould – Cantor Fitzgerald & Co., Research Division
Kerry Holford – Joh. Berenberg, Gossler & Co. KG, Research Division
Vamil Divan – Guggenheim Securities, LLC, Research Division
Christopher LoBianco – TD Cowen, Research Division
Asad Haider – Goldman Sachs Group, Inc., Research Division
Presentation
Operator
A good day, everyone, and welcome to Pfizer’s analyst and investor call to review the full year 2026 financial guidance. Today’s call is being recorded. At this time I would like to turn the call over to Francesca DeMartino, chief investor relations officer and senior vice president. Please go ahead, ma’am.
Francesca DeMartino
Chief Investor Relations Officer
Good morning, and welcome to Pfizer’s 2026 financial guidance call. I’m Francesca DeMartino, chief investor relations officer. On behalf of the Pfizer team, thank you for joining us. This call is being made available via audio webcast at Pfizer.com. Earlier this morning we released our 2026 financial guidance via a press release that is available at our website, Pfizer.com. I’m doing today by Dr. Albert Bourla, our Chairman and CEO, and Dave Denton, our CEO. Albert and Dave have prepared remarks and then we’ll open the call for questions. Before you get started I want to remind you that we’ll be making forward-looking
